Sampson currently serves as President of PrimaNova Technologies Limited, a medical device company developing next generation neurosurgical medical devices, in neuro monitoring, CSF management, and keyhole minimally invasive surgeries.
Previously, Sampson was Director of Investment and Business Development at China Medical System Holdings (“CMS”, HKEX: 0867), responsible for global BD transactions, biotech and medtech equity investments, and managing the company’s portfolio of life sciences VC fund investments. Prior to CMS, Sampson was Vice President at Delos Capital, a Hong Kong based life sciences VC fund specializing in early-stage biotech and medtech investment in the US and China, with responsibilities ranging from sourcing and execution of investment opportunities, to post-investment management and value creation.
In the early years of Sampson’s career, he had extensive transaction experience in global M&A and buyout investment, working in investment banking and private equity.
Sampson graduated from the University of Chicago with a Bachelor of Arts in Economics.